Sw Ine Flu Final
-
Upload
liza-mariposque -
Category
Health & Medicine
-
view
1.623 -
download
5
Transcript of Sw Ine Flu Final
![Page 1: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/1.jpg)
INFLUENZA A (H1N1)
LIZA D. MARIPOSQUE, M.D.2nd Year Family Med Resident
Perpetual Succour HospitalSeptember 2009
![Page 2: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/2.jpg)
OBJECTIVES:
To present a case of H1N1 in a 28 years old pregnant patient.
To discuss Influenza A H1N1 Epidemiology Signs & symptoms Risk factors Diagnosis Treatment and Prevention
![Page 3: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/3.jpg)
J. L., 28 years old, pregnantG4P1-1-1-2, 13 wks 6/7 days AOG by LMPMarriedFilipinoRoman CatholicSambag I, Cebu City admitted for the 4th times at PSH
CC: fever, cough & shortness of breath
![Page 4: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/4.jpg)
PAST MEDICAL HISTORY
Non-diabetic, non-hypertensive,
non-asthmatic.
Non-smoker, non-alcohol beverage drinker Allergy: shrimp
HFD: HPN, DM 2, Bronchial Asthma
![Page 5: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/5.jpg)
PAST MEDICAL HISTORY
2004 – PSH : NSVD (PT) 2005 – PSH : Ectopic pregnancy,
S/P Salpingectomy R 2008 – PSH : NSVD (FT)
2 wks PTA : Herpes Zoster infection
![Page 6: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/6.jpg)
OBSTETRICAL HISTORY
Menarche - 10 y.o x 28 days cycle 7 days duration
LMP: April 1, 2009 AOG: 13 wks & 6 days EDC: January 8, 2010
![Page 7: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/7.jpg)
HISTORY OF PRESENT ILLNESS
3 days PTA, sudden onset of fever with cough, coryza, headache & poor appetite.
Night PTA, had shortness of breath and spontaneously resolved, but recurred in the morning PTA thus prompted admission.
![Page 8: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/8.jpg)
PHYSICAL EXAMINATIONS
Examined conscious, coherent & slightly respiratory distress.
BP: 110/80 mmHg HR: 86 bpm
RR: 29 cpm T: 36.8 0C
Wt: 59.8 kg
![Page 9: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/9.jpg)
PHYSICAL EXAMINATION
SKIN: Fair, warm, no rashes, no cyanosis
HEENT: Anecteric sclerae, pinkish palpebral conjunctivae, nasal congestion, non-hyperemic tonsils.
NECK: No lymphadenopathy
C/L: Equal chest expansion, clear breath sounds, no rales, no wheeze.
![Page 10: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/10.jpg)
PHYSICAL EXAMINATION
ABDOMEN: Flabby, normoactive bowel sound, soft, nontender,
no hepatomegaly, no palpable mass.
GUT: fundus 4 fingerbreaths below umbilicus, FHT: 139 bpm, (-) KPS
EXT. : No edema, strong pulses, CRT <2 sec.CNS: WNL
![Page 11: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/11.jpg)
ADMITTING IMPRESSION
Upper Respiratory Tract Infection
PU 13 wks 6/7 AOG, Not in labor
![Page 12: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/12.jpg)
COURSE IN THE WARD
1ST HOSPITAL DAY
P: Cough, fever, coryza, shortness of breathS: w/ cough, w/ coryza O: conscious, coherent & not in respiratory
distress.BP: 100/70-110/80 mmHg PR: 76-85 bpm RR: 19-29 cpm T: 36.9-37.5 0C
![Page 13: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/13.jpg)
COURSE IN THE WARD
1ST HOSPITAL DAY
SKIN: Fair, warm, no rashes.HEENT: Anecteric sclerae, pinkish palpebral conjunctivae,
with both nasal congestionnasal congestion, non-hyperemic tonsils.NECK: No lymphadenopathyC/L: Equal chest expansion, clear breath sound, no rales,
no wheeze.ABDOMEN: Flabby, normoactive bowel sounds, soft,
nontender, no hepatomegaly, no mass.GUT: fundus 4 fingerbreaths below umbilicus
FHT: 139-160 bpm, (-) KPSEXT. : No edema, strong pulses, CRT <2 sec.CNS: WNL
![Page 14: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/14.jpg)
COURSE IN THE WARD
1ST HOSPITAL DAY
A: Influenza A
R/O Influenza H1N1
Pregnancy Uterine 13 wks 6/7 AOG, not in labor
![Page 15: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/15.jpg)
COURSE IN THE WARD1ST HOSPITAL DAY
P: > Oxygen inhalation.
> IVF started.
> Hypoallergenic diet.
> Labs: CBC, U/A, CXR w/ abdominal shield,
Screening test for Influenza A & B
![Page 16: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/16.jpg)
LABORATORY RESULTS
CBC N.V. RESULTS
WBC 4-11.30 6.42
Neutrophils 47-80% 72
Lymphocytes 13-40% 16
Monocytes 2-11% 10
Eosinophil 0-5% 1
Basophil 2-4% 1
Hb 12-16 13.2
Hct 36-46% 38.7
plt 140-440 235
![Page 17: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/17.jpg)
URINALYSIS RESULTS
Color & transparency Yellow, clear
Glucose NEG
Protein +
pH 6
Urine Ketone +
RBC/hpf 5-10 / hpf
WBC/hpf 0-2 / hpf
Epithelial cells rare
Mucus Threads abundant
Amorphous material rare
Bacteria rare
![Page 18: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/18.jpg)
(Rapid Qualitative Test)
Sample Type: Nasopharyngeal Swab
Results: (+) Influenza A
(-) Influenza B
SCREENING TEST FOR INFLUENZA A & B
![Page 19: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/19.jpg)
COURSE IN THE WARD1ST HOSPITAL DAY
P: >FHT monitoring BID.> Paracetamol 500 mg 4H prn for T≥38 0C & headache.> Sinupret 1 tab TID then revise to BID.> Salbutamol 1 neb q 6H.> Vit. C (Benutrex) 1 amp infused to present IVF ANST and in succeeding IVF to follow.> Prenatal Vit. (Beniforte) 1 cap OD is continued.> co-managed with OB.
![Page 20: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/20.jpg)
COURSE IN THE WARD
2nd Hospital Day
S: no complaints
O: BP: 100/70-120/80 mmHg
PR: 77-91 bpm
RR: 18-20 cpm
T: 36.7-37 0C
![Page 21: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/21.jpg)
COURSE IN THE WARD2nd Hospital Day
SKIN: Fair, warm, no rashes.HEENT: Anecteric sclerae, pinkish palpebral conjunctivae,
no nasal congestionno nasal congestion, non-hyperemic tonsils.NECK: No lymphadenopathyC/L: Equal chest expansion, clear breath sounds, no rales,
no wheeze.ABDOMEN: Flabby, normoactive bowel sound, soft,
nontender, no hepatomegaly, no mass.
GUT: fundus 4 fingerbreaths below umbilicus, FHT: 150-159 bpm , (-) KPSEXT. : No edema, strong pulses, CRT <2 sec.CNS: WNL
![Page 22: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/22.jpg)
COURSE IN THE WARD
2nd Hospital Day
P: > Confirmatory throat swab test for Influenza A H1N1 c/o DOH.
> IVF terminated.
> meds given.
![Page 23: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/23.jpg)
COURSE IN THE WARD3rd Hospital Day
S: No complaints
O: BP: 100/70-120/70 mmHg PR: 74-75 bpm RR: 18-19 cpm T: 36.4-36.7 0C
![Page 24: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/24.jpg)
COURSE IN THE WARD3rd Hospital Day
SKIN: Fair, warm, no rashes.HEENT: Anecteric sclerae, pinkish palpebral conjunctivae,
no nasal congestionno nasal congestion, non-hyperemic tonsils.
NECK: No lymphadenopathyC/L: Equal chest expansion, clear breath soundsclear breath sounds, no rales,
no wheeze.ABDOMEN: Flabby, normoactive bowel sound, soft,
nontender, no hepatomegaly, no mass.GUT: fundus 4 fingerbreaths below umbilicus
FHT: 149-150 bpm, (-) KPSEXT. : No edema, strong pulses, CRT <2 sec.CNS: WNL
![Page 25: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/25.jpg)
COURSE IN THE WARD3rd Hospital Day
A: > condition improved
> Patient discharge.
> Take home meds:
1. Bisolvon syr. 1 tbsp TID x 1 wk
2. Multivit. (Centrum) 1 cap OD
3. Beniforte 1 cap OD.
> Encourage oral fluid intake.
> ff-up with AP 1 wk after discharge.
![Page 26: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/26.jpg)
COURSE IN THE WARD3rd Hospital Day
Final Diagnoses:
Influenza A H1N1 Pregnancy Uterine 14 wks 1/7 AOG,
not in labor.
![Page 27: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/27.jpg)
Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
(+) NOVEL INFLUENZA A (H1) VIRAL RNA
![Page 28: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/28.jpg)
INFLUENZA Acute respiratory illness caused by infection with
influenza viruses.
Affects the upper and/or lower respiratory tract and is often accompanied by systemic signs and symptoms: fever - headache myalgia - weakness
![Page 29: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/29.jpg)
What is the Novel Influenza A (H1N1)?
Quadruple Reassortment 2 swine strains, 1 human strain, 1 avian strain of influenza
6 of 8 gene segments were similar to triple reassortant swine influenza viruses in pigs
1. Emergence of a Novel Swine-Origin Influenza A (H1N1)Virus in Humans. N Engl J Med 2009;3612. Epidemiology, clinical manifestations, and diagnosis of swine H1N1 influenza A. Uptodate, May 15, 2009
![Page 30: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/30.jpg)
Antigenic Variation
![Page 31: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/31.jpg)
![Page 32: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/32.jpg)
Influenza A virus Subtypes
16 different HA antigens (H1 to H16) 9 different NA antigens (N1 to N9) 3 subtypes of HA (H1, H2, and H3) &
2 subtypes of NA (N1 and N2) – caused human disease.
found in birds & pigs
![Page 33: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/33.jpg)
Immune responses to the H antigen are the major determinants of protection against infection with influenza virus.
N antigen limit viral spread and contribute to reduction of the infection.
![Page 34: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/34.jpg)
Emergence of Antigenic Subtypes of Influenza A Virus Associated with Pandemic or Epidemic Disease
Years Subtype Extent of Outbreak
1889–90 H2N8a Severe pandemic
1900–03 H3N8a ?Moderate epidemic
1918–19 H1N1b (formerly HswN1) Severe pandemic
1933–35 H1N1b (formerly H0N1) Mild epidemic
1946–47 H1N1 Mild epidemic
1957–58 H2N2 Severe pandemic
1968–69 H3N2 Moderate pandemic
1977–78c H1N1 Mild pandemic
![Page 35: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/35.jpg)
Late March and early April 2009 outbreak of H1N1 influenza A virus infection detected in Mexico several other countries
including the United States.
April 17, 2009 – CDC reported a novel H1N1 virus
![Page 36: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/36.jpg)
![Page 37: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/37.jpg)
The Western Pacific Region has reported a total 609 laboratory-confirmed cases of influenza A(H1N1): (WHO 5/29)
Japan 367 Australia 147 China 41 Republic of Korea 33 Zealand 9 Philippines 6 Singapore 4 Malaysia 2
![Page 38: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/38.jpg)
Cumulative total as of 13 Aug 2009
Cases* Deaths
WHO Regional Office for the Americas (AMRO) 105,882 1579
WHO Regional Office for the Western Pacific (WPRO) 27,111 50
WHO Regional Office for South-East Asia (SEARO) 13,172 106
WHO Regional Office for the Eastern Mediterranean (EMRO) 2532 8
WHO Regional Office for Africa (AFRO) 1469 3
Total 182,166 182,166 1,7461,746
![Page 39: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/39.jpg)
![Page 40: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/40.jpg)
Interspecies Transmission
![Page 41: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/41.jpg)
Person-to-person Transmission
Droplets spray.
No risk from eating pork
Transmissibility - higher compared with seasonal influenza
![Page 42: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/42.jpg)
Incubation period
for most cases ranges from 1 to 4 days
![Page 43: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/43.jpg)
Infectious - from 1 day prior to the development of signs and symptoms until resolution of fever
Contagious - until seven days after the onset of illness
Longer - in children (especially young infants), elderly adults, patients with chronic illnesses, and immunocompromised hosts.
![Page 44: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/44.jpg)
Most common clinical findings (642 confirmed cases):1
Fever (94%) Cough (92%) Soar throat (66%) Diarrhea (25%) Vomiting (25%)
Influenza-Like Illness (ILI)2
fever plus cough and/or sore throat
1. Emergence of a Novel Swine-Origin Influenza A (H1N1)Virus in Humans. N Engl J Med 2009;3612. Epidemiology, clinical manifestations, and diagnosis of swine H1N1 influenza A. Uptodate, May 15, 20093 CIDRAP
![Page 45: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/45.jpg)
Danger signs in all patients
shortness of breath dyspnea cyanosis bloody or coloured sputum chest pain altered mental status high fever that persists beyond 3 days hypotension
![Page 46: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/46.jpg)
Complications
Progressive Pneumonia Respiratory Failure – cause of most deaths Acute Respiratory Distress Syndrome
* In the U.S., most described cases have been mild
Anna R Thorner, MD. Treatment and prevention of swine H1N1 influenza. Uptodate, May 14, 2009.
![Page 47: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/47.jpg)
High Risk Groups for Complications
Children < 5 yrs. old > 50 years or older Children and adolescents
(age 6 months to 18 years) Pregnant women
Novel H1N1 Influenza (Swine Flu)http://www.cidrap.umn.edu/cidrap/content/influenza/swineflu/biofacts/swinefluoverview.html
![Page 48: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/48.jpg)
High Risk Groups for Complications
Adults & children w/ chronic pulmonary, cardiovascular, hepatic, hematological, neurologic, neuromuscular, or metabolic disorders
Immunocompromised Adults & children Residents of nursing homes and other chronic-
care facilities.
Novel H1N1 Influenza (Swine Flu)http://www.cidrap.umn.edu/cidrap/content/influenza/swineflu/biofacts/swinefluoverview.html
![Page 49: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/49.jpg)
DIAGNOSIS
![Page 50: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/50.jpg)
DIAGNOSTIC TEST Real-Time Reverse Transcription-Polymerase
Chain Reaction (rRT-PCR) Detection Qualitative for Influenza A, B, H1, and H3 positive for influenza A and negative for H1 and
H3 If reactivity of real-time RT-PCR for influenza A is
strong (eg, Ct <30), it is more suggestive of a novel influenza A virus.
Novel H1N1 Influenza (Swine Flu)http://www.cidrap.umn.edu/cidrap/content/influenza/swineflu/biofacts/swinefluoverview.html
![Page 51: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/51.jpg)
Tests Culture
Isolation of H1N1 influenza A virus - diagnostic too slow negative viral culture does not exclude H1N1
influenza A infection
* Priority for testing should be given to: Those who require hospitalization and Those who are at high risk for severe
complications
![Page 52: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/52.jpg)
Specimen
Upper Respiratory sample Intubated - endotracheal aspirate Placed in viral transport media and placed
on ice (4ºC) or refrigerated or in a -70ºC freezer
![Page 53: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/53.jpg)
CDC Case Definitions for Infection with Novel Influenza A (H1N1) Virus
Suspected case
does not meet the confirmed or probable case definition not novel H1N1 test–negative and is/has one of the following features:
Previously healthy, less than 65 years of age resides in a state without confirmed cases but has
traveled to a state or country where there is/are one or more confirmed or probable cases
has an epidemiologic link in the past 7 days to a confirmed case or probable case
cdc.com
![Page 54: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/54.jpg)
CDC Case Definitions for Infection with Novel Influenza A (H1N1) Virus
Probable case
Influenza-like-illness positive for influenza A, but is unsubtypable by
reagents used to detect seasonal influenza virus infection
cdc.com
![Page 55: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/55.jpg)
CDC Case Definitions for Infection with Novel Influenza A (H1N1) Virus
Confirmed case
Influenza-like-illness laboratory confirmed by one or more of
the following tests:• real-time RT-PCR
• viral culture
cdc.com
![Page 56: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/56.jpg)
Antiviral Treatment and Prophylaxis of Influenza
Age Group (years)
Antiviral Drug Children ( 12)
Oseltamivir
Treatment, influenza A and B Age 1–12, dose varies by weighta
Prophylaxis, influenza A and B Age 1–12, dose varies by weightb
Zanamivir
Treatment, influenza A and B Age 7–12, 10 mg bid by inhalation
Prophylaxis, influenza A and B Age 5–12, 10 mg qd by inhalation
Amantadinec
Treatment, influenza A Age 1–9, 5 mg/kg in 2 divided doses, up to 150 mg/d
Prophylaxis, influenza A Age 1–9, 5 mg/kg in 2 divided doses, up to 150 mg/d
Rimantadinec
Treatment, influenza A Not approved
Prophylaxis, influenza A Age 1–9, 5 mg/kg in 2 divided doses, up to 150 mg/d
![Page 57: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/57.jpg)
Recommended Treatment
supportive intravenous hydrations Antiviral agents
sensitive to oseltamivir and zanamivir resistant to amantadine and rimantadine
Anna R Thorner, MD. Treatment and prevention of swine H1N1 influenza. Uptodate, May 14, 2009.
![Page 58: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/58.jpg)
Oseltamivir (Tamiflu) Adult dose
Rx for acute illness: 75 mg PO bid for 5 d
Prophylaxis: 75 mg PO qd
available as 30-mg, 45-mg, and 75-mg oral capsules and as a powder for suspension that contains 12 mg/mL after reconstitution.
![Page 59: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/59.jpg)
Zanamivir (Relenza) Adult dose
Rx for acute illness: 10 mg inhaled orally bid for 5 d
Prophylaxis of household contact: 10 mg inhaled orally qd for 10 d (initiate within 36 h)
Prophylaxis for community outbreak: 10 mg inhaled orally qd for 28 d (initiate within 5 d of outbreak)
powder form for inhalation via the Diskhaler oral inhalation device
![Page 60: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/60.jpg)
Pregnant women
Oseltamivir and zanamivir are "Pregnancy Category C" medications
used only if the potential benefit justifies the potential risk to the embryo or fetus
cdc.com
![Page 61: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/61.jpg)
Post-exposure antiviral prophylaxis
Close contacts who are at high risk for complications individuals with certain chronic medical
conditions ≥ 65 years of age pregnant women
cdc.com
![Page 62: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/62.jpg)
Post-exposure antiviral prophylaxis
Health care workers, public health workers, or first responders who were not using appropriate personal protective equipment during close contact with a confirmed, probable, or suspected patient during that person's infectious period.
![Page 63: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/63.jpg)
Pre-exposure prophylaxis
only be used in limited situations ongoing occupational risk for exposure
healthcare workers public health workers first responders
cdc.com
![Page 64: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/64.jpg)
The single best way to protect against the flu is to get vaccinated each year.
flu shot— an inactivated
vaccine (containing killed virus). - for use in people older than 6 months, including healthy people and people with chronic medical conditions.
The nasal-spray flu vaccine —made with live, weakened flu viruses that do not cause the flu (LAIV or FluMist®). - approved for use in healthy* people, 2-49 y.o. who are not pregnant.
![Page 65: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/65.jpg)
Each vaccine contains three influenza viruses: one A (H3N2) virus one A (H1N1) virus one B virus
2 weeks after vaccination - antibodies that provide protection against influenza virus infection develop in the body.
![Page 66: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/66.jpg)
Influenza A H1N1 Vaccine Not yet available A European prototype of a swine flu vaccine
has been achieved Pandemic specific vaccines will not be
available until 4-6 months after a pandemic virus has emerged
![Page 67: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/67.jpg)
Pandemic influenza vaccine manufacturing process & timeline
![Page 68: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/68.jpg)
When to Get Vaccinated
Yearly flu vaccination should begin in September or as soon as vaccine is available and continue throughout the influenza season, into December, January, and beyond.
Timing & duration of influenza seasons vary.
![Page 69: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/69.jpg)
When H1N1 influenza is confirmed in a community (CDC recommends):
Home isolation School dismissal and childcare facility
closure Social distancing
![Page 70: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/70.jpg)
Preventive measures for health care personnel
single-patient room with the door kept closed An airborne-infection isolation room with
negative-pressure air handling. Suctioning, bronchoscopy, or intubation should
be performed in a procedure room with negative-pressure air handling.
Patients should wear a surgical mask when outside their room.
![Page 71: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/71.jpg)
Preventive measures for health care personnel
Frequently Hand washing & respiratory hygiene practices.
Routine cleaning and disinfection strategies Standard, droplet, and contact precautions
should be used for all patient care activities and maintained for 7 days after illness onset or until symptoms have resolved.
![Page 72: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/72.jpg)
Preventive measures for health care personnel
Personnel providing care to or collecting clinical specimens from patients should wear disposable nonsterile gloves, gowns, and eye protection (eg, goggles) to prevent conjunctival exposure.
![Page 73: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/73.jpg)
Preventive measures for health care personnel
personnel engaged in aerosol-generating activities (eg, collection of clinical specimens, endotracheal intubation, nebulizer treatment, bronchoscopy) and/or resuscitation involving emergency intubation or cardiac pulmonary resuscitation should wear a fit-tested disposable N95 respirator.
![Page 74: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/74.jpg)
Preventions for the Community:
Cover the mouth & nose when coughing and sneezing.
Always wash hands with soap & water. Use alcohol-based hand sanitizers. Avoid close contact with sick people. Increase body resistance.
![Page 75: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/75.jpg)
Travel Advisory
WHO is not recommending travel restrictions related to the outbreak of the influenza A(H1N1) virus
WHO do not believe entry and exit screenings would work to reduce the spread of this disease
May 15, 2009 - CDC Travel Health Warning for Novel H1N1 Flu in Mexico Removed
![Page 76: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/76.jpg)
Department Of Health
Oseltamivir (Tamiflu)
Designated referral centers2
National Referral Center Research Institute of Tropical Medicine (RITM)
Sub-national Referral Center Luzon & Metro Manila = San Lazaro Hospital Visayas = Vicente Sotto Memorial Medical
Center Mindanao = Davao Medical Center
1 Inquirer .net 2 DOH
![Page 77: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/77.jpg)
DOH Lines of Defense
1. Points of Exit and Entry Screening2. Enhanced Diseases Surveillance3. Preventive Measures4. Prescribed Drug of Choice: Oseltamivir5. Infection Control (N95 mask)6. Social Distancing7. Emergency powers: Martial Law
DOH National Epidemiology Center
![Page 78: Sw Ine Flu Final](https://reader036.fdocuments.net/reader036/viewer/2022062319/554aefb8b4c90559058b46ea/html5/thumbnails/78.jpg)
Thank You